Skip to main content
UCB's Global Corporate Website
instagram
facebook
twitter
youtube
linkedin
rss
Listen
24 Aug 2021
UCB Announces European Commission Approval of BIMZELX[®]▼ (bimekizumab) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis
Read More
20 Aug 2021
Disposals of own shares
Read More
13 Aug 2021
Disposals of own shares
Read More
9 Aug 2021
Transparency notification FMR LLC.
Read More
7 Aug 2021
New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis
Read More
6 Aug 2021
Disposals of own shares
Read More
2 Aug 2021
Disposals of own shares
Read More
29 Jul 2021
First half 2021 with sustainable performance – delivering on UCB’s strategy and guidance
Read More
23 Jul 2021
Disposals of own shares
Read More
Wendy
Read more
about Wendy
Pagination
First page
Previous page
‹ Previous
Page
1
Page
2
Page
3
Page
4
Current page
5
Page
6
Page
7
Page
8
Page
9
…
Next page
Next ›
Last page
Subscribe to
Choose a Country
Global Site – English
Australia – English
België – Engels
Belgique – Anglais
Brasil – Português
България – Български
Canada – English
Canada – Français
中国 – 中文
Česká Republika – Angličtina
Danmark – Engelsk
Deutschland – Deutsch
France – Français
España – Español
Ελλάδα – Ελληνικά
India – English
Ireland – English
Italia – Inglese
日本 – 日本語
한국 – 한국어
Luxembourg – Anglais
Luxemburg – Engels
Magyarország – Angol
México & Latinoamérica – Español
Nederland – Engels
New Zealand – English
Norge – Engelsk
Österreich – Deutsch
Polska – Polski
Portugal – español y portugués
România – Engleză
Россия – Русский
Slovensko – Anglický
Suomi – Englanti
Sverige – Engelska
Schweiz – Deutsch
Türkiye – Türkçe
Україна – Англійська
United Kingdom – English
U.S.A. – English
×
instagram
facebook
twitter
youtube
linkedin
rss